Scancell Holdings Plc, (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer, is pleased to announce that the United States Food and Drug Administration (‘FDA’) has granted orphan drug designation to its SCIB1 ImmunoBody® (‘SCIB1’) for the treatment of metastatic melanoma.
Orphan drug status in the United States qualifies the development of SCIB1 for a 50% tax credit for clinical trials, a waiver of the prescription drug user fee for the drug approval procedure and a period of seven years of market exclusivity following drug approval by the FDA. During the orphan market exclusivity period, the FDA cannot approve a NDA (new drug application) or a generic drug application for the same product including the principal molecular structure features of the drug and for the same rare disease indication.
The Orphan Drug Designation program provides orphan status to drugs and biologics which are defined as those intended for the safe and effective treatment, diagnosis or prevention of rare diseases/disorders that affect fewer than 200,000 people in the U.S., or that affect more than 200,000 persons but are not expected to recover the costs of developing and marketing a treatment drug.1
Richard Goodfellow, Joint CEO of Scancell, said: “The grant of orphan drug status gives SCIB1 further protection in our key US market in addition to our patent portfolio. We also welcome the financial incentives afforded by such a designation. Following encouraging data from Part 2 of our SCIB1 Phase I/II trial announced in December, development work continues apace and we look forward to disclosing data from additional patients receiving the 8mg dose in due course. ”
For Further Information:
Dr Richard Goodfellow, Joint CEOProfessor Lindy Durrant, Joint CEO
Scancell Holdings Plc
Scancell Holdings Plc
|+ 44 (0) 20 7831 3113|
|Camilla Hume/Stephen Keys||Cenkos Securities plc||+ 44 (0) 20 7397 8900|
|Mo Noonan/Simon Conway||FTI Consulting||+ 44 (0) 20 7831 3113|
Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms. Scancell’s first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is being evaluated in a Phase 1/2 clinical trial. Data from the trial demonstrate that SCIB1 produced a melanoma-specific immune response and promising survival trend
Scancell’s ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.
Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 that destroy tumours without toxicity. The Directors believe that the Moditope® platform could play a major role in the development of safe and effective cancer immunotherapies in the future.
<p> <a href="http://www.proactiveinvestors.co.uk/LON:SCLP/Scancell-Holdings-Plc/" class="companyPopupTrigger" rel="3362">Scancell Holdings Plc</a> (<a href="http://www.proactiveinvestors.co.uk/LON:SCLP/Scancell-Holdings-Plc/" class="companyPopupTrigger" rel="3362">LON:SCLP</a>) has confirmed it will kick off a phase II clinical trial of its potentially breakthrough cancer treatment in the second half.</p> <p> CEO Richard Goodfellow also tells Proactive's Andrew Scott they've found a partner to help them with a phase I/II clinical study of SCIB2 for patients with lung cancer.</p> Wed, 01 Feb 2017 09:53:00
The update was provided as Scancell served up its financial results for the six months ended October 31.Tue, 31 Jan 2017 08:01:00